Psoriatic Arthritis

Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.

In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.

In round two of our ongoing psoriatic arthritis quiz series, we focus on treatment recommendations made in the 2018 ACR/NPF psoriatic arthritis treatment guidelines. We also include a puzzler based on findings from a newly published study.

Active psoriatic arthritis and ankylosing spondylitis can lead to adverse pregnancy outcomes, which grows with corticosteroid use, a study shows.

A review article confirms low adherence and persistence rates for medication compliance in rheumatoid arthritis, psoriasis and psoriatic arthritis. Patients with higher adherence rates had better outcomes.

The TNF-inhibitor biosimilar was shown to fare similarly to the marketed therapy in a 52-week efficacy trial.

Patients affected by psoriatic arthritis may benefit from both pharmacologic and non-pharmacologic treatments. In this slideshow, we outline the recommendations from the ACR and the National Psoriasis Foundation.

Patient access to biologic therapies is an issue throughout the European Union where the authors of a review article zero in on “why.” Access issues, they find, have a lot in common with access issues here in the U.S.

Rheumatoid arthritis, psoriasis and psoriatic arthritis patients have consistently low levels of biologic adherence and persistence. How can patient compliance be improved? Lower out-of-pocket costs, utilize specialty pharmacies and improve patient education.

Study shows there is no substantial difference in cardiovascular risk associated with different biologic therapies for psoriasis and psoriatic arthritis patients.

In this slideshow, we address the treatment recommendations for adults with active psoriatic arthritis despite previous treatment with biologics.

The 2018 American College of Rheumatology and the National Psoriasis Foundation released updated treatment guidelines for psoriatic arthritis (PsA). Test your knowledge of the current therapeutic recommendations for PsA in this quiz.

Biological therapies prescribed for rheumatic diseases may also reduce their long-term risks of cardiovascular diseases (CVD), new research shows.

A new study in JAMA Dermatology raises an interesting question for physicians who treat psoriasis patients. Does methotrexate work best in patients with plaque psoriasis alone or patients who have both psoriasis and arthritis?

Calprotectin is a known marker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Now, researchers reporting in Arthritis Research and Therapy say that baseline calprotectin levels may predict disease relapse for RA and PsA patients on TNFi therapy. Learn more in this slideshow. 

The January issue of Arthritis and Rheumatology includes updated treatment guidelines for adults with active psoriatic arthritis. In this article, we take a comprehensive look at the guidelines.

The immunosuppressive drug was more effective and resulted in fewer adverse events in patients with psoriasis but without psoriatic arthritis.

New joint guidelines by the American College of Rheumatology and National Psoriasis Foundation recommend psoriatic arthritis patients receive a treat-to-target approach, first-line use of tumor necrosis factor inhibitors biologics, and smoking cessation.

How much confidence do you have in your treatment target?

Take this 5-question quiz to find out.

The approval was based on a comprehensive data package demonstrating that Hyrimoz matches the reference biologic in terms of safety, efficacy, and quality.

Does interval training have a place in the management of PsA?

But cardiovascular risk is similar to that seen in patients with psoriasis.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

British researchers quantified the burden of continuing weight gain on the risk of PsA.